Cancer Research Meeting Calendar EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Half, E.
Right arrow Articles by Sinicrope, F. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Half, E.
Right arrow Articles by Sinicrope, F. A.
[Cancer Research 62, 1676-1681, March 15, 2002]
© 2002 American Association for Cancer Research

Clinical Investigations

Cyclooxygenase-2 Expression in Human Breast Cancers and Adjacent Ductal Carcinoma in Situ1

Elizabeth Half, Xi Ming Tang, Karin Gwyn, Aysegul Sahin, Kyle Wathen and Frank A. Sinicrope2

Departments of Gastrointestinal Medicine and Nutrition [E. H., X. M. T., F. A. S.], Breast Medical Oncology [K. G.], and Biomathematics [K. W.] and Division of Pathology [A. S.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

Cyclooxygenase-2 (COX-2) is an inducible enzyme that converts arachidonic acid to prostaglandins. Overexpression of the COX-2 gene in mammary glands of transgenic mice was sufficient to induce tumorigenesis. We analyzed COX-2 expression in human breast cancers (and breast cancer cell lines) and adjacent ductal carcinoma in situ (DCIS) as well as its association with HER2/neu and clinicopathological variables. Archival primary breast carcinomas (n = 57), adjacent DCIS (n = 14) and DCIS alone (n = 2) were analyzed for COX-2 and HER2 expression by immunohistochemistry using specific monoclonal antibodies. An immunohistochemical scoring system was used. HER2 gene amplification had been analyzed previously by fluorescence in situ hybridization (n = 20). Histology of carcinomas included infiltrating ductal (n = 44), lobular (n = 2), and other (n = 7). Frozen breast cancers and adjacent normal tissue pairs (n = 9) were analyzed for COX-2 mRNA by reverse transcription-PCR. COX-2 and HER2 expression were also analyzed in human breast cancer cell lines (MCF-7, MCF-7/HER2, SK-BR-3, and MDA-MB-231) by immunoblotting. Cytoplasmic COX-2 expression was detected at an intermediate or high level in epithelial cells in 18 of 42 (43%) invasive breast cancers and in 10 of 16 (63%) cases of DCIS. Normal-appearing breast epithelia adjacent to cancer expressed COX-2 in 81% of cases and was generally focal and of similar or decreased intensity relative to adjacent neoplastic epithelia. COX-2 mRNA was detected in all samples analyzed by reverse transcription-PCR and was increased in eight of nine breast cancers relative to paired normal tissue. In archival tumors, no significant correlation was found between COX-2 and HER2 expression/amplification and clinicopathological variables. COX-2 expression was induced in MCF-7 cells stably transfected with HER2, in contrast to parental MCF-7 cells, and was detected in MDA-MB-231, but not SK-BR-3 cells. COX-2 is frequently overexpressed in invasive breast cancers and in adjacent DCIS and, thus, may be an early event in mammary tumorigenesis. Forced HER2 expression in MCF-7 cells was shown to up-regulate COX-2, although no association was found in human tumors. Our results suggest that nonsteroidal anti-inflammatory drugs and selective COX-2 inhibitors may be useful in the chemoprevention and therapy of human breast cancer.




This article has been cited by other articles:


Home page
 Anticancer ResHome page
M. THILL, D. FISCHER, S. BECKER, T. CORDES, C. DITTMER, K. DIEDRICH, D. SALEHIN, and M. FRIEDRICH
Prostaglandin Metabolizing Enzymes in Correlation with Vitamin D Receptor in Benign and Malignant Breast Cell Lines
Anticancer Res, September 1, 2009; 29(9): 3619 - 3625.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K.-Y. Chang, M.-R. Shen, M.-Y. Lee, W.-L. Wang, W.-C. Su, W.-C. Chang, and B.-K. Chen
Epidermal Growth Factor-activated Aryl Hydrocarbon Receptor Nuclear Translocator/HIF-1{beta} Signal Pathway Up-regulates Cyclooxygenase-2 Gene Expression Associated with Squamous Cell Carcinoma
J. Biol. Chem., April 10, 2009; 284(15): 9908 - 9916.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. Falandry, P. A. Canney, G. Freyer, and L. Y. Dirix
Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer
Ann. Onc., April 1, 2009; 20(4): 615 - 620.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. E. Abraham, P. Harrington, K. E. Driver, J. Tyrer, D. F. Easton, A. M. Dunning, and P. D.P. Pharoah
Common Polymorphisms in the Prostaglandin Pathway Genes and Their Association with Breast Cancer Susceptibility and Survival
Clin. Cancer Res., March 15, 2009; 15(6): 2181 - 2191.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
P. Fernandez, P. M. de Beer, L. van der Merwe, and C. F. Heyns
COX-2 promoter polymorphisms and the association with prostate cancer risk in South African men
Carcinogenesis, December 1, 2008; 29(12): 2347 - 2350.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. R. Molina, S. H. Kaufmann, J. M. Reid, S. D. Rubin, M. Galvez-Peralta, R. Friedman, K. S. Flatten, K. M. Koch, T. M. Gilmer, R. J. Mullin, et al.
Evaluation of Lapatinib and Topotecan Combination Therapy: Tissue Culture, Murine Xenograft, and Phase I Clinical Trial Data
Clin. Cancer Res., December 1, 2008; 14(23): 7900 - 7908.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
J. R. Neil, K. M. Johnson, R. A. Nemenoff, and W. P. Schiemann
Cox-2 inactivates Smad signaling and enhances EMT stimulated by TGF-{beta} through a PGE2-dependent mechanisms
Carcinogenesis, November 1, 2008; 29(11): 2227 - 2235.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
E.-M. Boneberg, D. F. Legler, H.-J. Senn, and G. Furstenberger
Reduced Expression of Cyclooxygenase-2 in Primary Breast Cancer
J Natl Cancer Inst, July 16, 2008; 100(14): 1042 - 1043.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
X. Zhao, M. Goswami, N. Pokhriyal, H. Ma, H. Du, J. Yao, T. A. Victor, K. Polyak, C. D. Sturgis, H. Band, et al.
Cyclooxygenase-2 Expression during Immortalization and Breast Cancer Progression
Cancer Res., January 15, 2008; 68(2): 467 - 475.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
I. Stasinopoulos, D. R. O'Brien, F. Wildes, K. Glunde, and Z. M. Bhujwalla
Silencing of Cyclooxygenase-2 Inhibits Metastasis and Delays Tumor Onset of Poorly Differentiated Metastatic Breast Cancer Cells
Mol. Cancer Res., May 1, 2007; 5(5): 435 - 442.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
K. L Henriksen, B. B Rasmussen, A. E Lykkesfeldt, S. Moller, B. Ejlertsen, and H. T Mouridsen
Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays
J. Clin. Pathol., April 1, 2007; 60(4): 397 - 404.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H.-T. Kim, G. Kong, D. DeNardo, Y. Li, I. Uray, S. Pal, S. Mohsin, S. G. Hilsenbeck, R. Bissonnette, W. W. Lamph, et al.
Identification of Biomarkers Modulated by the Rexinoid LGD1069 (Bexarotene) in Human Breast Cells Using Oligonucleotide Arrays
Cancer Res., December 15, 2006; 66(24): 12009 - 12018.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. Jimeno, M. L. Amador, P. Kulesza, X. Wang, B. Rubio-Viqueira, X. Zhang, A. Chan, J. Wheelhouse, H. Kuramochi, K. Tanaka, et al.
Assessment of celecoxib pharmacodynamics in pancreatic cancer
Mol. Cancer Ther., December 1, 2006; 5(12): 3240 - 3247.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Lanza-Jacoby, R. Burd, F. E. Rosato Jr., K. McGuire, J. Little, N. Nougbilly, and S. Miller
Effect of Simultaneous Inhibition of Epidermal Growth Factor Receptor and Cyclooxygenase-2 in HER-2/Neu-Positive Breast Cancer.
Clin. Cancer Res., October 15, 2006; 12(20): 6161 - 6169.
[Abstract] [Full Text] [PDF]

Home page
 Vet PatholHome page
M. Brunelle, E. A. Sartin, L. G. Wolfe, J. Sirois, and M. Dore
Cyclooxygenase-2 expression in normal and neoplastic canine mammary cell lines.
Vet. Pathol., September 1, 2006; 43(5): 656 - 666.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
G. D. Basu, T. L. Tinder, J. M. Bradley, T. Tu, C. L. Hattrup, B. A. Pockaj, and P. Mukherjee
Cyclooxygenase-2 Inhibitor Enhances the Efficacy of a Breast Cancer Vaccine: Role of IDO
J. Immunol., August 15, 2006; 177(4): 2391 - 2402.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I. Wolf, J. O'Kelly, T. Rubinek, M. Tong, A. Nguyen, B. T. Lin, H.-H. Tai, B. Y. Karlan, and H. P. Koeffler
15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer.
Cancer Res., August 1, 2006; 66(15): 7818 - 7823.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
K J Schmitz, R Callies, J Wohlschlaeger, R Kimmig, F Otterbach, J Bohr, H-S Lee, A Takeda, K W Schmid, and H A Baba
Overexpression of cyclo-oxygenase-2 is an independent predictor of unfavourable outcome in node-negative breast cancer, but is not associated with protein kinase B (Akt) and mitogen-activated protein kinase (ERK1/2, p38) activation or with Her-2/neu signalling pathways
J. Clin. Pathol., July 1, 2006; 59(7): 685 - 691.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
H. Zhi, L. Wang, J. Zhang, C. Zhou, F. Ding, A. Luo, M. Wu, Q. Zhan, and Z. Liu
Significance of COX-2 expression in human esophageal squamous cell carcinoma
Carcinogenesis, June 1, 2006; 27(6): 1214 - 1221.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
G. K. Yiu and A. Toker
NFAT Induces Breast Cancer Cell Invasion by Promoting the Induction of Cyclooxygenase-2
J. Biol. Chem., May 5, 2006; 281(18): 12210 - 12217.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. R. Howe, S.-H. Chang, K. C. Tolle, R. Dillon, L. J.T. Young, R. D. Cardiff, R. A. Newman, P. Yang, H. T. Thaler, W. J. Muller, et al.
HER2/neu-Induced Mammary Tumorigenesis and Angiogenesis Are Reduced in Cyclooxygenase-2 Knockout Mice
Cancer Res., November 1, 2005; 65(21): 10113 - 10119.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. H. Kim, V. Bossuyt, T. Ponn, D. Lannin, and B. G. Haffty
Cyclooxygenase-2 Expression in Postmastectomy Chest Wall Relapse
Clin. Cancer Res., July 15, 2005; 11(14): 5199 - 5205.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. Altundag
Challenge in the Treatment of Estrogen-Receptor-Negative Ductal Carcinoma in Situ
J. Clin. Oncol., July 1, 2005; 23(19): 4469 - 4470.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
G. Kong, H.-T. Kim, K. Wu, D. DeNardo, S. G. Hilsenbeck, X.-C. Xu, W. W. Lamph, R. Bissonnette, A. J. Dannenberg, and P. H. Brown
The Retinoid X Receptor-Selective Retinoid, LGD1069, Down-regulates Cyclooxygenase-2 Expression in Human Breast Cells through Transcription Factor Crosstalk: Implications for Molecular-Based Chemoprevention
Cancer Res., April 15, 2005; 65(8): 3462 - 3469.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. L. Gauthier, C. R. Pickering, C. J. Miller, C. A. Fordyce, K. L. Chew, H. K. Berman, and T. D. Tlsty
p38 Regulates Cyclooxygenase-2 in Human Mammary Epithelial Cells and Is Activated in Premalignant Tissue
Cancer Res., March 1, 2005; 65(5): 1792 - 1799.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
K. Muller-Decker, I. Berger, K. Ackermann, V. Ehemann, S. Zoubova, S. Aulmann, W. Pyerin, and G. Furstenberger
Cystic Duct Dilatations and Proliferative Epithelial Lesions in Mouse Mammary Glands upon Keratin 5 Promoter-Driven Overexpression of Cyclooxygenase-2
Am. J. Pathol., February 1, 2005; 166(2): 575 - 584.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
G. D. Basu, L. B. Pathangey, T. L. Tinder, M. LaGioia, S. J. Gendler, and P. Mukherjee
Cyclooxygenase-2 Inhibitor Induces Apoptosis in Breast Cancer Cells in an In vivo Model of Spontaneous Metastatic Breast Cancer
Mol. Cancer Res., November 1, 2004; 2(11): 632 - 642.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Lanza-Jacoby, A. P. Dicker, S. Miller, F. E. Rosato, J. T. Flynn, S. N. Lavorgna, and R. Burd
Cyclooxygenase (COX)-2-dependent effects of the inhibitor SC236 when combined with ionizing radiation in mammary tumor cells derived from HER-2/neu mice
Mol. Cancer Ther., April 1, 2004; 3(4): 417 - 424.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
D. Wang and R. N. DuBois
Cyclooxygenase 2-derived prostaglandin E2 regulates the angiogenic switch
PNAS, January 13, 2004; 101(2): 415 - 416.
[Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
S. Lanza-Jacoby, S. Miller, J. Flynn, K. Gallatig, C. Daskalakis, J. L. Masferrer, B. S. Zweifel, H. Sembhi, and I. H. Russo
The Cyclooxygenase-2 Inhibitor, Celecoxib, Prevents the Development of Mammary Tumors in HER-2/neu Mice
Cancer Epidemiol. Biomarkers Prev., December 1, 2003; 12(12): 1486 - 1491.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
H. Choy and L. Milas
Enhancing Radiotherapy With Cyclooxygenase-2 Enzyme Inhibitors: A Rational Advance?
J Natl Cancer Inst, October 1, 2003; 95(19): 1440 - 1452.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Davies, J. Salter, M. Hills, L.-A. Martin, N. Sacks, and M. Dowsett
Correlation between Cyclooxygenase-2 Expression and Angiogenesis in Human Breast Cancer
Clin. Cancer Res., July 1, 2003; 9(7): 2651 - 2656.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
N. M. Gajraj
Cyclooxygenase-2 Inhibitors
Anesth. Analg., June 1, 2003; 96(6): 1720 - 1738.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
V. Shim, M. L. Gauthier, D. Sudilovsky, K. Mantei, K. L. Chew, D. H. Moore, I. Cha, T. D. Tlsty, and L. J. Esserman
Cyclooxygenase-2 Expression Is Related to Nuclear Grade in Ductal Carcinoma in Situ and Is Increased in Its Normal Adjacent Epithelium
Cancer Res., May 15, 2003; 63(10): 2347 - 2350.
[Abstract] [Full Text] [PDF]

Home page
 Vet PatholHome page
M. Dore, I. Lanthier, and J. Sirois
Cyclooxygenase-2 Expression in Canine Mammary Tumors
Vet. Pathol., March 1, 2003; 40(2): 207 - 212.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. J. Levitt and M. Pollak
Insulin-like Growth Factor-I Antagonizes the Antiproliferative Effects of Cyclooxygenase-2 Inhibitors on BxPC-3 Pancreatic Cancer Cells
Cancer Res., December 15, 2002; 62(24): 7372 - 7376.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Sun, X. M. Tang, E. Half, M. T. Kuo, and F. A. Sinicrope
Cyclooxygenase-2 Overexpression Reduces Apoptotic Susceptibility by Inhibiting the Cytochrome c-dependent Apoptotic Pathway in Human Colon Cancer Cells
Cancer Res., November 1, 2002; 62(21): 6323 - 6328.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.